Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab and imatinib in advanced GIST
NCT03609424Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Feb 2019
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of spartalizumab in gastrointestinal stromal tumor (GIST), sponsored by Asan Medical Center. Started Feb 2019; status: completed.
02
Drugs
spartalizumab
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT03609424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03609424.